Related Experiment Video

Updated: Jan 6, 2026

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

16.1K

Detection by screening introduces biases into survival estimates for luminal A-like breast cancer patients

Lauro Bucchi1, Alessandra Ravaioli1, Silvia Mancini1

  • 1Romagna Cancer Registry, Romagna Cancer Institute (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST, IRCCS), Meldola, Forlì, Italy.

International Journal of Cancer
|October 3, 2019
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence
06:52

Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence

Published on: November 5, 2021

3.6K
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.7K

Related Experiment Videos

Last Updated: Jan 6, 2026

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

16.1K
Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence
06:52

Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence

Published on: November 5, 2021

3.6K
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.7K

Related Concept Videos

Kaplan-Meier Approach01:24

Kaplan-Meier Approach

526
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
526
Cancer Survival Analysis01:21

Cancer Survival Analysis

624
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
624

Articles linked to this work by shared authors, journal, and citation graph.

Post-VABB Cavity-Targeted Avidin-Pretargeted [90Y]Y-DOTA-Biotin in Nonpalpable Breast Cancer: A Phase I Activity-Escalation Study (ARTHE).

Cancers·2026

Predictive biomarkers in cancer immunotherapy for genitourinary malignancies.

Critical reviews in oncology/hematology·2026

Immune Checkpoint Inhibitor-Related Pneumonitis in Renal Cell Carcinoma: Clinical Features, Mechanisms, and Lessons from Lung Cancer.

Biomolecules·2026

Embarking on a new era in high-risk biochemical recurrent prostate cancer: redefining early systemic intervention.

Pharmacology & therapeutics·2026

Radiological review of interval breast cancers following screening with DBT + DM or DM: results from MAITA project randomized trials.

La Radiologia medica·2026

Prevalence and Cure of Primary Liver Cancer in Italy by Histologic Type.

Cancers·2026

Epigenetic Predictors of Smoking: External Validation and Association With Smoking-Related Cancer Risk.

International journal of cancer·2026

Limited Assessment of Proportional Hazards Despite More Frequent Violations Identified in Updated Oncology Trial Analyses: Frequency, Patterns, and Statistical Implications.

International journal of cancer·2026

Improved Prediction of Colon Cancer Recurrence Using the ColoNode mRNA Test: A 5-Year Survival Analysis.

International journal of cancer·2026

Randomized Prospective Comparison Between Neoadjuvant Mitomycin C Plus Cisplatin and Paclitaxel Plus Carboplatin in Patients With BRCA1-Associated Ovarian Cancer.

International journal of cancer·2026

Lifestyle Factors Associated With Colorectal Adenomas: Results From a Vietnamese Case-Control Study.

International journal of cancer·2026

Gene Expression Biomarkers for Breast Ductal Carcinoma in Situ Recurrence Prediction.

International journal of cancer·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us